News
M2S announces new Clinical Trial product, iMAS, for medical image collect and hold solution
West Lebanon, NH – July 29, 2009: M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, today announced that it has launched a new product to collect and hold medical images in clinical trials, called iMAS (Image Management Archive System). iMAS is a cost-effective option for clinical trial sponsors to centralize the collection of the large imaging data sets frequently utilized in clinical trials, while giving them accessibility and secure storage, with minimal investment.
"Clinical trial sponsors are facing extraordinary cost pressures in the current economy,” said Wes Chapman, CEO of M2S. “With less time needed for setup, decreased trial complexity and reduced documentation requirements, an M2S iMAS trial is typically only 20% of the cost of a full clinical trial. This option gives trial sponsors the control and flexibility to adjust a trial and add a blinded radiological review at any point, while simultaneously containing costs."
While many clinical trials continue to incorporate imaging data for surrogate endpoints, it is not always clear whether or not image data review and submission will be necessary. However, potentially valuable and expensive imaging data can and probably should still be collected. Sponsors may want to consider using those images for a later submission, subsequent trials or for patient registries, and the risk, cost and effort of retrospectively collecting images can exceed that of prospective medical image collection. M2S will customize the iMAS product based on service levels needed for a particular clinical trial – including consultation, project management and query management. Real-time, web-based reports allow sponsors to see both the status of data gathered as well as access the data anytime, anywhere. Transparency and flexibility for the sponsor, as well as the ability to reduce a sponsor’s risk through proactive image management strategies, are the cornerstones of iMAS’ success.
About M2S, Inc.
M2S offers medical image data management services across the healthcare continuum based on best-in-class technology and continuous quality improvement processes. M2S clinical trial image management services include protocol development, electronic image collection, independent review, archive and real-time web-based data access. M2S clinical data registries provide long-term evaluation of treatment outcomes, benefits and cost. All services focus on increasing operational efficiency, reducing total cost and maintaining or enhancing clinical quality. For more information, visit www.m2s.com.
M2S, Inc. Makes Contribution to American Vascular Association
West Lebanon, NH - February 11, 2009: M2S, Inc. a global provider of image management services for endovascular imaging and medical device clinical trials announced that it has made a contribution to the Open the Pathway campaign of the American Vascular Association (AVA). Open the Pathway is an initiative that was established to improve vascular health. M2S has a long-term commitment to vascular treatment planning, post-operative patient outcomes and medical data registries. With their contribution, M2S will hold a seat on the Industry Advisory Council, where members of the vascular medicine community come together to discuss critical topics facing the industry.
Open the Pathway was launched in July 2008 by the AVA as a fundraising effort uniting vascular surgeons and corporate partners in generating vital resources for education and research. Its mission is to ensure quality patient care through the discovery of new and safer methods to treat vascular disease. The M2S contribution helps support research conducted by vascular surgeons and keeps the specialty of vascular surgery current and in the forefront of a world where technologies and medicines are constantly changing.
“As a company that has embraced technological advances and combined them with medical imaging to provide vascular surgeons powerful informational tools, we are pleased to be part of the AVA’s mission to further advance treatments for people suffering from vascular disease all over the world,” M2S CEO Wes Chapman said.
About the American Vascular Association
AVA is the charitable foundation of the Society for Vascular Surgery (SVS), a not-for-profit society that seeks to advance excellence and innovation in vascular health through education, advocacy, research and public awareness. SVS is the national advocate for 2,700 vascular surgeons dedicated to the prevention and cure of vascular disease. For more information visit the SVS website at www.VascularWeb.org.
About M2S, Inc.
M2S provides 3-D endovascular imaging and data management services for endovascular treatment planning and clinical trials. It is the leading provider of AAA and TAA Treatment Planning utilizing its Preview® Software/Services and its PEMS® (Patient Endovascular Management Services) registry for the vascular surgery field. M2S develops and maintains custom image and medical data registry products for industry and clinical medicine.
M2S has been a supporter of the SVS over the past several years participating in SVS’ Vascular Annual Meeting® and other SVS related programs. For more on M2S, visit www.m2s.com.
M2S, Inc. Acquires DXA Resource Group
West Lebanon, NH –December 31, 2008: M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Massachusetts. Founded in 2002, DRG recognized the need for cost-effective and responsive DXA (Dual- Emission X-Ray Absorptiometry) clinical quality assurance, project management and data management services to support drug development. DXA, a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition, is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for osteoporosis, HIV, obesity, growth hormone deficiency, endometriosis, fibroids and Gaucher’s disease.
“DRG has integrated quality service with imaging data technology, which exactly fits into the M2S mission and clinical trials image management service offering. The addition of DRG allows M2S to further expand our capabilities and therapeutic expertise, and meet the growing demand for image management services worldwide,” M2S CEO Wes Chapman said.
“Adding M2S high-speed image collection and trial management technologies to DRG’s proprietary quality system and data management, enables us to greatly increase our presence in the drug development market,” said Reta Rupich, President of DXA Resource Group.
About M2S, Inc.
M2S provides image and data management services for clinical trials sponsors in the biopharmaceutical and medical device industries, patient registry databases and is a recognized leader in 3-D endovascular treatment planning. For the past 10 years, M2S has managed, under protocol, millions of images from around the globe in various therapeutic areas and in all DICOM modalities. For more information, visit www.m2s.com.
About DXA Resource Group
DXA Resource group is a clinical trials service company focused on providing customer-centric, cost-effective quality assurance as well as data and project management for clinical trials involving Dual X-ray Absorptiometry (DXA) measurements. For more information visit www.dxaresourcegroup.com or www.m2s.com.
M2S, Inc. Achieves Milestone with 150,000th Scan for Evaluation and Surveillance of Aortic Aneurysms
West Lebanon, NH –November 7, 2008: M2S Inc., an industry leader in endovascular treatment planning and patient registries, announced today that the company has reached a new milestone, having processed over 150,000 radiographic scans for evaluation and surveillance of aortic aneurysms. With each scan received, M2S evaluates approximately 1,000 images, pushing M2S’ total images received and processed to over 150 million.
From each scan, M2S provides 3D reconstruction, measurement and registry services to physicians across the country, providing more accuracy and efficiency for endovascular aortic aneurysm pre-operative planning and post-operative surveillance. The pre- and post-operative analyses are posted to M2S’ PEMS® website, providing physicians 24/7 access to their patient data and images. Utilizing the Preview® treatment planning software from M2S, physicians can also interactively view the 3D model, as well as virtually implant stent grafts onto the 3D model to further optimize the visualization of treatment.
M2S provides image and data management services and registries for endovascular treatment planning and clinical trials. Their services are designed to improve health care and reduce the time and cost of clinical trials. For the past 10 years, M2S has worked with many of the world’s leading academic centers, pharmaceutical companies, and medical device manufacturers, managing under protocol, millions of images from around the globe.
M2S, Inc. expands global coverage- announces partnership with ResearchPoint Global
West Lebanon, NH – January 8, 2008: M2S Inc., an industry leader in medical image management and analysis, announced today that it has entered into a partnership agreement with ResearchPoint Global (RPG), a joint-venture, full-service CRO with an established presence in nearly 70 countries. M2S provides superior image management, state-of-the-art 3D modeling, and cutting edge image analysis to the pharmaceutical, biotech, surgical, and medical device industries. The partnership with RPG is the next step in M2S’ international growth for its Clinical Trials Services division.
The partnership will provide M2S’ clinical trials clients with access to RPG’s integration of services, including inter- national regulatory support, patient recruitment, and site selection and management. In addition, the partnership will help M2S expand its rapidly growing business with offices, sites, and experienced personnel in over 70 countries, while supporting the global deployment of its proprietary image transfer technology.
M2S’s CEO, Wes Chapman, said, “We’re pleased to be a part of the RPG network. RPG delivers the highest standard of quality in customer service while continually seeking innovative and cost-effective solutions to their clients’ needs. This new partnership will allow clinical investigators working on a global level to focus more freely on what they do best, rather than on the art, science, and logistics of core lab image processing and management – which is what we do best. The global expansion of our technology and the extension of our services will serve our clients well and help secure our plans to become the preeminent image management company.”
President and CEO of ResearchPoint and founding partner of RPG, John Farinacci notes, “We are pleased to now offer our clients comprehensive imaging services to support their clinical trial objectives. The collaboration with M2S and the imaging capabilities they offer creates seamless delivery between clinical monitoring and imaging management ac- tivities. RPG will now be able to collect and manage image data, and support independent reviews, whether centralized, remote, regional or global. Imaging services will reside at each of our global locations to ensure security and real-time monitoring.”
M2S’s DICOM ArmorCarTM (DACTM) image transfer technology has revolutionized the way medical images are trans- ported between sites, core labs, and clinical trial sponsors. The DACTM transfers image data securely in their original digital DICOM format for immediate, real-time QC assessment and query generation/resolution. In addition to its pres- ervation of data integrity, the DACTM provides incredible time savings and eliminates the immense costs associated with storing data on CDs and shipping them via courier, a standard practice in the industry today. The DAC is the first system designed specifically to address these significant issues, and the expansion of its global integration will allow clinical trial sponsors to utilize its power to manage their large international trials more efficiently and cost-effectively than ever before. DACs have already been installed and implemented in over 250 institutions in the U.S.A., as well as a growing number in Europe, South America, and Asia.
About M2S
M2S is a pioneer and leader in imaging core lab services and data management technology for clinical trials. For the past 15 years the company has worked with many of the world’s leading academic centers, managing, under protocol, over 25 million images from around the globe. M2S develops image-based systems and protocols that reduce time, costs and uncertainty for the healthcare discovery and delivery community.
About ResearchPoint Global
ResearchPoint Global is a joint venture comprised of global CROs and technology service providers. ResearchPoint Global (RPG) has 14 development partners and maintains a presence in nearly 70 countries. Each of these companies has a customer-centric focus and track record of success with pharmaceutical, biotechnology and medical device companies. The ResearchPoint Global team uses a continuum model of integrated clinical develop- ment services to expedite product development and improve the outsourcing experience for customers and investigators.